Top Stories
Some of the firm's portfolio companies will be able to use agentic AI technology for drug discovery and operations automation.
The regimen combines the KLK2/CD3 bispecific antibody pasritamig and the PSMA/CD28 costimulatory bispecific antibody JNJ-9401.
The purchase will add a macrocyclic peptide discovery engine to argenx's growing immunology capabilities.
The oral drug, which blocks the IL-23 receptor, showed joint and skin improvements in the ICONIC-PsA 1 study.
Novo's IL-6 inhibitor failed to reduce CV death, non-fatal heart attack or non-fatal stroke in high-risk patients With ASCVD despite substantial biomarker reductions.
Conference News
· First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activate T cells against...
120-session hybrid conference in Barcelona will bring together leading researchers and clinicians to explore biomarkers, disease mechanisms and novel therapeutic strategies.GENEVA, Nov. 9, 2026 /PRNew...
UTSW-led study in Colombia and Jamaica finds nearly 70% of patients reached blood pressure goal when multiple medications were combined into one8-Nov-2026 at 3:30 PM EST, by UT Southwestern Medical Ce...
American Heart Association Scientific Sessions 2026, Late-Breaking Science Abstract 23117Research Highlights:In a randomized clinical trial of more than 300 adults, ages 55 years and older in China wi...
SHANGHAI, Nov. 8, 2026 /PRNewswire/ -- Clopidogrel does not work the same way in every patient. In East Asian populations the gap is wider still: a share of patients get too little platelet inhibition...
